Lista de obras - Jonathan H Schatz - Dominio Público Uruguay

A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma

artículo científico publicado en 2017

A network of RNA-binding proteins controls translation efficiency to activate anaerobic metabolism

artículo científico publicado en 2020

A rare presentation of in situ mantle cell lymphoma and follicular lymphoma: a case report and review of the literature

artículo científico publicado en 2014

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

artículo científico publicado en 2013

A translational program that suppresses metabolism to shield the genome

artículo científico publicado en 2020

ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A.

artículo científico publicado en 2017

CRISPR genome editing of murine hematopoietic stem cells to create Npm1-Alk causes ALK+ lymphoma after transplantation

artículo científico publicado en 2019

Central Nervous System Involvement by Small Lymphocytic Lymphoma after a Myxoma-Related Embolic Event

artículo científico publicado en 2019

Complications of Intrathecal Chemotherapy in Adults: Single-Institution Experience in 109 Consecutive Patients.

artículo científico publicado en 2019

Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.

artículo científico publicado en 2016

Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis.

artículo científico publicado en 2010

Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?

artículo científico publicado en 2017

Double hit lymphoma presenting as haemophagocytic lymphohistiocytosis.

artículo científico publicado en 2017

Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors

artículo científico publicado en 2015

Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy

artículo científico publicado en 2014

Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation

scientific article published on 01 August 2006

Kinase overexpressing cancers responsive to drug withdrawal.

artículo científico publicado en 2015

Mouse models of cancer as biological filters for complex genomic data ⬇️

artículo científico publicado el 27 de septiembre de 2010

Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells

artículo científico publicado en 2015

Optimized doxorubicin chemotherapy for diffuse Large B-Cell lymphoma exploits nanocarrier delivery to transferrin receptors

artículo científico publicado en 2020

Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.

artículo científico publicado en 2017

Progress against follicular lymphoma

artículo científico

RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer

artículo científico publicado en 2014

Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation

artículo científico publicado en 2019

Sirolimus (rapamycin) induced proteinuria in a patient undergoing allogeneic hematopoietic stem cell transplant.

artículo científico publicado en 2008

Statins enhance efficacy of venetoclax in blood cancers.

artículo científico publicado en 2018

Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1

artículo científico publicado en 2015

T Cell-Activating Bispecific Antibodies in Cancer Therapy

artículo científico publicado en 2019

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.

artículo científico publicado en 2016

Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with Antitumor Activity

artículo científico publicado en 2018

Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis.

artículo científico publicado en 2014

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

artículo científico publicado en 2011

Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies

artículo científico publicado en 2011

The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma

scientific article published on 05 December 2019

Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.

artículo científico publicado en 2018

eIF4A inhibition: ready for primetime?

artículo científico publicado en 2018

Lista de obras de Jonathan H Schatz

A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma

A network of RNA-binding proteins controls translation efficiency to activate anaerobic metabolism

A rare presentation of in situ mantle cell lymphoma and follicular lymphoma: a case report and review of the literature

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

A translational program that suppresses metabolism to shield the genome

ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A.

CRISPR genome editing of murine hematopoietic stem cells to create Npm1-Alk causes ALK+ lymphoma after transplantation

Central Nervous System Involvement by Small Lymphocytic Lymphoma after a Myxoma-Related Embolic Event

Complications of Intrathecal Chemotherapy in Adults: Single-Institution Experience in 109 Consecutive Patients.

Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.

Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis.

Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?

Double hit lymphoma presenting as haemophagocytic lymphohistiocytosis.

Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors

Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy

Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation

Kinase overexpressing cancers responsive to drug withdrawal.

Mouse models of cancer as biological filters for complex genomic data ⬇️

Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells

Optimized doxorubicin chemotherapy for diffuse Large B-Cell lymphoma exploits nanocarrier delivery to transferrin receptors

Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.

Progress against follicular lymphoma

RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer

Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation

Sirolimus (rapamycin) induced proteinuria in a patient undergoing allogeneic hematopoietic stem cell transplant.

Statins enhance efficacy of venetoclax in blood cancers.

Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1

T Cell-Activating Bispecific Antibodies in Cancer Therapy

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.

Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with Antitumor Activity

Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis.

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies

The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma

Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.

eIF4A inhibition: ready for primetime?